🔬 Emerging Research for Aspergillosis

Aspergillosis is a complex group of diseases caused by the Aspergillus fungus. Ongoing research is uncovering new ways to diagnose, treat, and prevent these conditions—offering hope for improved care and long-term outcomes. This page outlines current areas of promising research relevant to patients, carers, and healthcare professionals.

⏱️ Has Research Accelerated Over Time?

Yes. Over the last 40 years, research into aspergillosis and fungal infections has significantly accelerated due to:

  • Rising awareness of fungal diseases in immunocompromised patients
  • Improved diagnostic technology (e.g. PCR, lateral flow tests, next-gen sequencing)
  • New drug development in response to growing azole resistance
  • Greater investment from both academic institutions and industry
  • Dedicated centres like the UK National Aspergillosis Centre driving specialist research
  • Fungal infections gaining WHO recognition as emerging public health threats

In the 1980s and 1990s, progress was relatively slow. Since the early 2000s—and especially after the COVID-19 pandemic revealed the risks of fungal co-infection—momentum has increased markedly.

1. 🧪 Antifungal Drug Development

Resistance to azole antifungals is a growing concern. Several new antifungal agents are in development:

🔸 Olorofim (F2G)

  • First-in-class orotomide antifungal
  • Shows activity against Aspergillus, including azole-resistant strains
  • Currently in phase III trials for invasive and chronic pulmonary aspergillosis

🔸 Ibrexafungerp and Fosmanogepix

  • New antifungals with different mechanisms of action
  • Potentially effective in combination or for resistant cases

🔸 Inhaled Antifungals

  • Trials of inhaled itraconazole, posaconazole, and PC945 (opelconazole) for direct delivery to the lungs
  • Aim: higher local drug concentrations with fewer side effects

2. 🧬 Biologics and Immune Modulation

🧭 What's Next in Biologic Therapies for Severe Asthma?

Several next-generation biologics are under development, aiming to:

  • Broaden coverage for patients who don't respond to existing biologics
  • Target upstream pathways (beyond IL‑5, IL‑4/13, or IgE)
  • Offer once-yearly dosing or dual-target activity

Examples include:

  • Depemokimab: A long-acting anti-IL‑5 antibody in phase 3 trials (GSK)
  • CSJ117: An inhaled anti-TSLP monoclonal antibody fragment (Novartis)
  • RG6354: Targeting IL-33 pathway, an upstream trigger in type 2 and non-type 2 asthma
  • Dual Biologics: Exploratory research combining two targets (e.g., IL‑5 + IL‑4 or TSLP + IL‑13)

These developments may also benefit subsets of aspergillosis patients with severe asthma or ABPA who have not fully responded to current biologics. Research is exploring biologic therapies that reduce allergic inflammation or modulate immune response, particularly for ABPA (Allergic Bronchopulmonary Aspergillosis) and overlapping asthma subtypes.

✅ Biologics Currently in Use for ABPA

Omalizumab (Xolair) – Anti-IgE

  • Target: IgE antibody—blocks allergic immune response to Aspergillus antigens.
  • Evidence: Studies show significant reductions in exacerbations, IgE, steroid use, and improved lung function.
  • Clinical Use: Widely used off-label in ABPA patients with raised IgE and asthma features.

Mepolizumab (Nucala) – Anti–IL‑5

  • Target: IL‑5 cytokine—reduces eosinophil inflammation.
  • Use: Steroid-sparing and symptom control in eosinophilic ABPA.

Benralizumab (Fasenra) – Anti–IL‑5 Receptor

  • Target: IL‑5Rα—causes rapid eosinophil depletion.
  • Use: Clearing mucus plugs and reducing flares; often used after mepolizumab failure.

Dupilumab (Dupixent) – Anti–IL‑4Ra

  • Target: IL‑4/IL‑13 pathway—type 2 inflammation.
  • Use: Shown to reduce IgE levels and ABPA exacerbations.

Tezepelumab (Tezspire) – Anti‑TSLP

  • Target: TSLP—broadly suppresses upstream allergic inflammation.
  • Evidence: Early reports suggest benefit in ABPA patients, though data are limited.

📊 Real-World Effectiveness

UK-based retrospective study (2014–2022):

  • 74 ABPA patients treated with biologics
  • 65% showed ≥50% reduction in steroid use after 12 months
  • 35% switched due to lack of effect or side effects

📌 Summary Table of Biologics

Biologic Target Use in Aspergillosis Key Benefits
Omalizumab IgE ABPA with raised IgE ↓ Exacerbations, ↓ steroids, ↑ FEV₁
Mepolizumab IL‑5 Eosinophilic ABPA Steroid-sparing, symptom control
Benralizumab IL‑5Rα Refractory cases Mucus clearance, eosinophil depletion
Dupilumab IL‑4/IL‑13 Mixed allergic/eosinophilic ABPA ↓ IgE, ↓ flares
Tezepelumab TSLP Emerging, broad asthma-ABPA Broad inflammation control

3. 🧫 Diagnostic Advances

Improved diagnostics aim to detect disease earlier and more accurately:

  • Lateral flow tests (e.g., Aspergillus-specific LFD) for rapid diagnosis
  • PCR testing and galactomannan assays in blood, sputum, or BAL
  • Aspergillus-specific IgG and IgE testing to distinguish CPA, ABPA, and colonisation
  • Next-generation sequencing (NGS) for strain typing and resistance detection

4. 🌡️ Non-Pharmacological Research

🌀 Airway Clearance and Physiotherapy

  • Trials assessing flutter devices, oscillating PEP, and manual physiotherapy in chronic aspergillosis and bronchiectasis

🥦 Nutrition and Gut-Lung Health

  • Increasing interest in the role of dietary fibre, gut microbiome, and short-chain fatty acids in immune defence and lung inflammation

💨 Air Quality and Exposure

  • Home-based studies evaluating the impact of HEPA filters, spore counts, and environmental remediation

5. 🛡️ Preventative Strategies

🫁 Lung/Nasal Coatings (Experimental)

  • Early research into coating the lungs or nasal passages to prevent infection
  • Not yet in human trials for aspergillosis, but promising in animals for viral and bacterial prevention

💉 Vaccines

  • No approved vaccines yet, but exploratory work is underway for high-risk populations

6. 🧫 Clinical Trials in Aspergillosis

A wide range of clinical trials are currently underway or recently completed, focusing on new antifungals, biologics, and non-pharmacological interventions:

🧪 Antifungal Trials

  • Rezafungin – A long-acting echinocandin administered once weekly, currently in trials for prevention and treatment of invasive fungal infections, including those caused by Aspergillus species
  • Olorofim (F2G) – Phase III trials for CPA and invasive aspergillosis
  • PC945 (Opelconazole) – Inhaled triazole for CPA and prophylaxis in immunocompromised patients
  • Fosmanogepix and Ibrexafungerp – Investigated in resistant and invasive fungal disease

🧬 Biologic Trials

  • Tezepelumab and Dupilumab – Trials involving patients with ABPA and severe asthma
  • Depemokimab (GSK) – Phase III trials for long-acting IL‑5 blockade

🌡️ Other Trials

  • Airway clearance studies – Use of physiotherapy and flutter/PEP devices in chronic pulmonary aspergillosis
  • Gut microbiome and fibre supplementation – Exploring anti-inflammatory potential in lung disease

These trials often recruit patients from UK centres including the National Aspergillosis Centre, and are registered on databases such as ClinicalTrials.gov.

7. 🤝 Patient Support and Outcomes Research

📊 Real-World Evidence

  • Registries and observational studies (e.g., LIFE, FungiScope) gathering long-term data on patients with CPA, ABPA, SAFS, and invasive disease

👥 Quality of Life and Patient-Reported Outcomes

  • Surveys and tools to measure impact of fatigue, breathlessness, mental health, and medication side effects
  • Aim: improve personalised care and support services

🧭 Where to Find Updates

  • ClinicalTrials.gov – searchable by "aspergillosis"
  • Aspergillosis.org – for patient-friendly research summaries
  • National Aspergillosis Centre (UK) – involved in many UK-based studies
  • Journal of Fungi, Medical Mycology, Clinical Infectious Diseases – leading sources of peer-reviewed studies

📢 Final Word

Research into aspergillosis is accelerating across drug development, diagnostics, prevention, and patient support. While not all options are available yet, many are in trials or early clinical use. Staying informed and involved—whether through trial participation or feedback—helps shape better care for all.

Updated July 2025 – suitable for patients, clinicians, and advocacy groups.

 

by GAtherton

🫁 Could Lung or Nasal Coatings Help Prevent Aspergillosis?

As research into new ways of preventing lung infections advances, some patients with aspergillosis are asking whether coating the lungs or airways—with a protective spray, gel, or surfactant—might one day protect them from fungal disease.

Here’s what the science says so far.

🔬 What Is Being Researched?

Scientists are currently studying ways to coat the lungs or nasal passages with a protective substance designed to:

  • Trap or neutralise viruses, bacteria, or fungal spores
  • Stabilise the lung or airway lining
  • Prevent inflammation or infection from taking hold

These coatings may come in the form of:

  • Dry powder aerosols (inhaled)
  • Drug-free nasal gels or sprays

Importantly, these are being developed as preventative measures, not as treatments for people already ill.

🧪 Current Research: Early-Stage, Not Yet for Aspergillosis

1. Dry Powder Lung Surfactants

  • These are based on natural surfactants that coat the lungs and keep the air sacs (alveoli) open.
  • Tested in animals (e.g., lambs, rabbits) with good results in preventing respiratory distress or injury.
  • Used mostly in neonatal care for premature babies.
  • Not yet tested for fungal infections or chronic diseases like aspergillosis.

2. Nasal Gel-Coating Sprays

  • These sprays form a temporary coating in the nose and upper airways, shown in mice to block viruses like flu or COVID-19.
  • Protective effect may last several hours.
  • Still in animal testing—no human trials or approvals yet.
  • No evidence yet that they can prevent fungal infections like Aspergillus.

📌 Are These Coatings Available Yet?

No. As of now:

  • There are no licensed lung or nasal sprays designed to prevent aspergillosis or other fungal lung infections.
  • Most studies are in pre-clinical stages (animal research only).
  • It may be several years before any human trials begin.

🛡️ Who Might Receive These Preventatives in the Future?

If future research proves these coatings are safe and effective, likely priority groups would include:

🎯 High-risk populations:

  • People with chronic aspergillosis (CPA) or ABPA
  • Patients on long-term steroids or immunosuppressants
  • Individuals with bronchiectasis, COPD, or cystic fibrosis
  • Transplant recipients or those with cancer or immune deficiencies
  • Elderly people, especially in care homes
  • Healthcare or construction workers exposed to dust, spores, or mould
  • Hospitalised or ventilated patients (e.g. risk of CAPA in ICU)

❗ What Aspergillosis Patients Should Know

  • These technologies are not available yet and remain in the research phase.
  • They are being explored as preventative tools, not as treatment for existing fungal infections.
  • There is no evidence yet they can prevent Aspergillus infections—but the research is promising.

✅ What You Can Do Now

Until better preventatives are developed, people with aspergillosis can reduce risk by:

  • Avoiding high-risk environments (e.g., compost, renovation dust, decaying vegetation)
  • Using prescribed antifungals or steroids correctly
  • Supporting immune health (e.g., good nutrition, rest, fibre-rich diet)
  • Asking doctors about biologics or ongoing research trials if relevant

📘 Final Word

While the idea of coating the lungs or nose to stop infections sounds futuristic, it’s grounded in real science. For people vulnerable to fungal lung disease, this kind of innovation may one day offer protection—especially for those on immunosuppressive treatments or with fragile lungs.

But for now, the best defence remains personalised treatment, avoidance strategies, and good communication between specialists and GPs. We’ll keep watching this space closely as research develops.

by GAtherton

Biologics and Long Term Side Effects

✅ What Are Biologics?

Biologics are targeted treatments made from living cells. They work by blocking parts of the immune system that cause inflammation — for example:

  • IL-4, IL-5, IL-13: linked to eosinophilic inflammation

  • IgE: linked to allergies and ABPA

They are not immunosuppressants like steroids or chemotherapy, but rather immune modulators.

💊 Long-Term Side Effects – What Do We Know?

👨‍⚕️ What research and experience show:

Biologic Used for Long-term safety known? Side effects most reported
Omalizumab (Xolair) Allergic asthma, ABPA 20+ years of use Injection site reactions, headache, very rare anaphylaxis
Mepolizumab (Nucala) Eosinophilic asthma, CPA 10+ years Fatigue, headache, shingles (rare), mild infections
Benralizumab (Fasenra) Severe asthma, CPA ~6–7 years Headache, pharyngitis, injection site issues
Dupilumab (Dupixent) Asthma, eczema, nasal polyps 6–8 years Eye dryness/redness, cold sores, joint pain (rare)
Tezepelumab (Tezspire) Severe asthma ~2 years Sore throat, joint pain, injection site reactions

⚠️ Possible Long-Term Concerns (but rare)

  • Infections: Some concern about slightly increased risk of herpes zoster (shingles) or respiratory viruses, but overall risk is very low compared to steroids.

  • Immunogenicity: Your body might develop antibodies to the drug over time, reducing its effect — this is more a loss of benefit, not a dangerous side effect.

  • Cancer risk: No consistent evidence linking asthma/ABPA biologics to cancer.

  • Unknowns: Because some biologics are new (e.g. tezepelumab), we don't yet have 20-year data — but so far the safety profile is reassuring.

🩺 Compared to Oral Steroids

Treatment Side Effects Over Time
Steroids (e.g. prednisolone) Weight gain, diabetes, infections, bone thinning, cataracts, adrenal suppression
Biologics Mostly minor – injection site pain, headache, mild infection risk, rare allergic reaction

So in most cases, biologics reduce the need for steroids and therefore reduce long-term harm.

💬 Patient Experience

Most patients report:

  • Improved quality of life

  • Reduced asthma/ABPA attacks

  • Fewer hospital visits

  • Very few stop due to side effects

✅ Summary

Question Answer
Do biologics have long-term side effects? Usually mild and rare; mostly injection reactions or mild infections
Are they safer than long-term steroids? Yes, especially over years
Should I be worried? Not usually — but always monitor with your team
How long have they been used? 6–20+ years, depending on the biologic, with very good safety data

by GAtherton

🛡️ How Your Care is Changing: Understanding Antimicrobial Stewardship

A guide for patients with aspergillosis and chronic lung conditions

If you're being treated for chronic pulmonary aspergillosis (CPA), ABPA, or any long-term lung condition, you might notice changes in the way doctors use antifungal and antibiotic medicines. These changes are part of a worldwide effort to tackle antimicrobial resistance (AMR) — and to make sure the right treatment is used, in the right place, for the right reason.

💬 What is Antimicrobial Stewardship?

Antimicrobial stewardship (AMS) means using antifungal and antibiotic medications responsibly, so they work better now and stay effective for the future.

It’s about:

  • Using the right medication

  • In the right place

  • For the right reason

  • At the right dose and duration

This helps ensure patients get better faster, and we all stay protected from drug-resistant infections.

🔬 What Is Antimicrobial Resistance?

Antimicrobial resistance (AMR) happens when bacteria or fungi evolve and stop responding to medicines that used to work. This makes infections:

  • Harder to treat

  • More likely to come back

  • More dangerous for people with lung or immune conditions

There are two major types:

  • Antibiotic resistance (bacteria)

  • Antifungal resistance (fungi, including Aspergillus fumigatus)

💊 Antibiotics: Broad vs Narrow Spectrum

Doctors aim to use targeted antibiotics wherever possible. Here’s how they differ:

Type Description Examples Used For
Broad-spectrum Kills a wide range of bacteria Co-amoxiclav, meropenem, ceftriaxone Sepsis, serious infections
Narrow-spectrum Targets specific bacteria Penicillin, nitrofurantoin, flucloxacillin Simple infections

🧪 Doctors may start with broad-spectrum drugs in emergencies but switch to narrow-spectrum when test results are available — this is called de-escalation.

🦠 Antifungal Resistance and Aspergillosis

People with CPA or ABPA are often treated with antifungals like:

  • Itraconazole

  • Voriconazole

  • Posaconazole

  • Isavuconazole

But fungi can develop resistance, especially when:

  • Medications are used long-term

  • Fungi are exposed to azole sprays on crops and flowers

You may inhale resistant spores from:

  • Compost, potting soil, or garden centres

  • Fresh flowers (especially imported ones)

🏥 What Might You Notice in Hospital?

✅ Shorter or targeted treatment

  • You may be on 5–7 days of antibiotics/antifungals

  • Switch from IV to tablets happens earlier once you're stable

✅ Treatment reviews

  • Your medication will be reviewed within 48–72 hours

  • Changes may be made based on lab results

✅ More testing

  • Blood, sputum, or biopsy samples help identify infections and resistance

  • Ensures you get the right treatment

✅ Specialist involvement

  • An infection or respiratory consultant may review your case if resistant infection is suspected

✅ Infection control

  • You may notice:

    • No fresh flowers

    • HEPA filters in some wards

    • Staff using extra precautions to prevent airborne infections

🏡 What Might You Notice From Your GP?

✅ More specific prescribing

  • GPs are less likely to give antibiotics “just in case”

  • More narrow-spectrum choices based on the suspected infection

✅ Diagnostic support

  • GPs may send sputum or urine samples before prescribing

  • May test your blood for antifungal levels (TDM)

✅ Home safety advice

You may be advised to:

  • Avoid indoor compost or plant pots

  • Wear FFP2/FFP3 masks when gardening

  • Keep indoor air well ventilated

🧬 New Antifungals Being Protected for Patient Use

Several antifungals are in development and being reserved just for medical use (not agriculture), including:

Drug What it is Why it matters
Rezafungin Weekly IV echinocandin Long-lasting for serious infections
Ibrexafungerp First oral alternative to azoles Trials for aspergillosis
Olorofim New class (DHODH inhibitor) Active against resistant Aspergillus
Opelconazole Inhaled antifungal Direct treatment to the lungs
Fosmanogepix Novel target Works against drug-resistant fungi

🧠 What This All Means for You

These changes are about:

  • Better outcomes — faster recovery with fewer side effects

  • Preventing resistance — protecting future treatments

  • More personalised care — based on test results and your condition

✅ What You Can Do

Action Why It Helps
Take medications exactly as prescribed Prevents underdosing and resistance
Don’t stop treatment early Even if you feel better
Ask if your treatment has been reviewed Encourages early switch or adjustment
Use a mask and gloves for gardening Reduces spore exposure
Avoid fresh flowers and compost indoors Especially in bedrooms or when unwell
Report any new or worsening symptoms Resistance may be developing
Ask about resistance testing if you’re not improving Labs can check fungal response
Stay informed and speak up You’re part of the stewardship solution

📌 In Summary: Stewardship in Action

Antimicrobial stewardship is not about doing less — it's about doing things more precisely.
It’s how your healthcare team makes sure you receive:

The right medication, in the right place, for the right reason.

🔗 Want to Learn More?

by GAtherton

💊 General Strategies to Reduce Antimicrobial Resistance in Clinical Practice

1. IV to Oral Switch (IVOS)

One of the most effective and safe interventions in antimicrobial stewardship.

🔁 Why switch from IV to oral early?

  • Reduces complications (e.g. line infections, thrombosis)

  • Lowers costs and bed-days

  • Improves patient comfort and mobility

  • Oral options (e.g. ciprofloxacin, fluconazole, linezolid) are highly bioavailable, often matching IV efficacy

✅ When is IVOS appropriate?

  • Clinical improvement seen

  • Source controlled

  • Oral route available and tolerated

  • Suitable oral alternative exists

NHS guidance: "Start smart – then focus" encourages early IVOS reviews within 48–72 hours of antibiotic initiation.

2. "Start Smart – Then Focus" (UK NHS Framework)

This key NHS antimicrobial policy includes:

  • Start Smart: Prescribe antibiotics appropriately from the beginning

  • Then Focus:

    • Review at 48–72 hours

    • Consider stop, switch, change, or continue

    • Document clearly in records

Supported by NICE guidelines and UKHSA audits

3. Shorter Duration of Therapy

For many infections, shorter courses (e.g. 5–7 days instead of 10–14) are now preferred.

Examples:

  • Community-acquired pneumonia: 5 days

  • Pyelonephritis: 7 days

  • Cellulitis: 5–7 days

This reduces resistance pressure and side effects.

4. Diagnostics-Guided Prescribing

  • Procalcitonin and CRP tests can help distinguish bacterial from viral infections

  • Rapid PCR, MRSA, or blood culture diagnostics guide targeted therapy

The aim is avoid empirical broad-spectrum antibiotics where possible.

5. Restricted Prescribing Policies

  • Certain high-risk drugs (e.g. carbapenems, vancomycin, antifungals) are restricted to ID approval

  • Antimicrobials are tiered by risk (e.g. traffic light systems) to encourage narrow-spectrum use

6. Antimicrobial Stewardship Teams (ASTs)

Multidisciplinary teams:

  • Lead on stewardship strategy

  • Audit antimicrobial use

  • Provide decision support for complex cases

  • Educate staff and update local formularies

In the NHS, stewardship is a CQUIN target (incentivised performance indicator).

7. Education and Behaviour Change

  • Mandatory AMS training for junior doctors and prescribers

  • Behavioural nudges in electronic prescribing systems (e.g. default shorter durations, alert for IVOS)

8. Surveillance and Reporting

  • ePAMS+, ESPAUR, and PHE Fingertips dashboards track:

    • Prescribing by hospital/unit

    • Resistance trends

    • Audit compliance with IVOS, duration, and documentation

9. Patient-Facing Initiatives

  • "Antibiotic Guardian" and leaflets explaining viral vs bacterial infections

  • Empowering patients to ask:

    "Do I really need antibiotics? When can I switch to tablets?"

📦 Summary Table: Key Interventions

Strategy Purpose
IV to Oral Switch Reduce IV duration, speed discharge
Review at 48–72 hrs Reassess need, de-escalate if possible
Shorter therapy courses Lower resistance pressure
Targeted diagnostics Support narrow-spectrum prescribing
Prescribing restrictions Protect last-resort antimicrobials
Stewardship teams Oversee, audit, educate
Surveillance & feedback Monitor trends, guide policy

by GAtherton

🦠 Antifungal Resistance: What It Is, How It Happens, and Why It Matters

Antifungal resistance is a growing global health threat, especially for people with lung conditions like chronic pulmonary aspergillosis (CPA) or allergic bronchopulmonary aspergillosis (ABPA). Just like bacteria can become resistant to antibiotics, fungi like Aspergillus fumigatus can develop resistance to antifungal drugs — making infections harder or even impossible to treat.

🔍 What Is Antifungal Resistance?

Antifungal resistance occurs when fungi evolve in ways that allow them to survive exposure to medications that used to kill them or stop their growth. This makes standard treatments less effective and increases the risk of:

  • Treatment failure

  • Prolonged illness

  • More severe infections

  • Increased hospital stays and costs

  • Higher death rates in vulnerable patients

🧬 How Does It Develop?

Fungi become resistant through genetic changes, often due to:

  • Long-term antifungal treatment in patients

  • Widespread environmental exposure to antifungal chemicals — especially azoles used on crops

Once resistance develops, the fungus may stop responding to key drugs like:

  • Itraconazole

  • Voriconazole

  • Posaconazole

  • Isavuconazole

These are the mainstays of treatment for aspergillosis and other serious fungal infections.

🌾 The Role of Agriculture: A Hidden Driver

Many resistant strains of Aspergillus don’t develop in people — they develop in the environment, especially in farmland and flower production areas.

Why?

The azole fungicides used on crops are chemically very similar to the azoles used in human medicine. They target the same fungal enzyme (CYP51, involved in cell wall formation). Fungi exposed repeatedly to these sprays can adapt — and the resulting resistant spores can:

  • Survive in soil, compost, and plant debris

  • Be carried on the wind

  • Be inhaled by people — especially those with weakened lungs or immune systems

High-risk areas include:

  • Grain farming (wheat, barley, maize)

  • Fruit production (apples, grapes, citrus)

  • Ornamental flowers (e.g., roses, tulips, chrysanthemums) — especially when imported or mass-grown

  • Garden centres and potting compost

🏠 Exposure at Home: Flowers, Soil, and More

People may unknowingly bring resistant Aspergillus spores into their homes through:

  • Fresh cut flowers (especially from florists using treated imports)

  • Potting compost or stored bulbs

  • Uncovered soil and plant material indoors

This is particularly dangerous for those with lung conditions, suppressed immunity, or recent surgery.

Practical tips:

  • Avoid keeping fresh flowers or pot plants in bedrooms or living areas

  • Use gloves and masks (FFP2 or FFP3) when handling soil or compost

  • Ventilate indoor spaces after gardening

💊 What’s Being Done: Medical, Policy, and Drug Development

1. Reserving drugs for clinical use

New antifungal drugs with novel mechanisms are being designed exclusively for medical use. Some are already approved or in late clinical trials:

Drug Type / Mechanism Status Notes
Rezafungin Echinocandin (IV, once-weekly) Approved 2023 (US/EU) For Candida, with long half-life
Ibrexafungerp Oral glucan synthase inhibitor Approved 2021 (US) Active against resistant Candida, in trials for Aspergillus
Oteseconazole Oral tetrazole Approved 2022 (US) Less toxicity, fewer interactions
Olorofim Pyrimidine synthesis inhibitor Late trials First in class, active against Aspergillus
Fosmanogepix GWT1 enzyme inhibitor Trials New target, good against multi-drug resistant fungi
Opelconazole Inhaled azole Trials Direct lung delivery, potential for aspergillosis

Many of these drugs are being deliberately withheld from agriculture to protect their effectiveness.

2. Policy & regulation

  • The “One Health” approach is gaining ground: it recognises the links between human, animal, and environmental health.

  • Some countries are monitoring soil and air for resistant fungi (e.g. Netherlands, UK).

  • Campaigns are underway to regulate or ban agricultural use of triazoles that drive cross-resistance.

  • Hospitals increasingly restrict fresh flowers in high-risk wards to protect immunocompromised patients.

🧭 What Needs to Happen Next

  • Tighter coordination between agricultural and medical authorities to regulate antifungal use

  • Incentives for developing safer, non-cross-reactive fungicides for farming

  • Increased global surveillance of resistant fungi in both clinical and environmental settings

  • Patient and public education about the risks and how to reduce exposure

🧠 What Patients Can Do

If you live with aspergillosis, chronic lung disease, or weakened immunity:

✅ Take your antifungal medicine exactly as prescribed
✅ Don’t stop or change treatment without medical advice
✅ Ask about resistance testing if symptoms worsen
✅ Avoid exposure to soil, compost, and fresh flowers
✅ Use respiratory protection (FFP2/FFP3 masks) in dusty or mouldy environments
✅ Advocate for better public policies on antifungal stewardship

🔗 Want to Learn More?

by GAtherton

Article 4: Why This New Information on Biofilms Can Be Reassuring — Not Frightening

💬 A Message to Patients: Why This New Information Can Be Reassuring — Not Frightening

We understand that learning about things like biofilms, the lung microbiome, or how different bugs work together might feel a little overwhelming or even alarming. These topics are complex and unfamiliar to many.

But we want you to know: this science is already improving care for people with aspergillosis — and you don’t need to understand every detail for it to help you.

✅ Examples of How Biofilm Awareness Is Already Helping Patients

🧪 1. Combined Treatment for Coinfection

People who have both Aspergillus and Pseudomonas infections are now more likely to be:

  • Tested for both microbes

  • Given combination therapy (e.g. antifungals + inhaled antibiotics)
    This reduces the risk of persistent symptoms and lowers the chance of hospital admission.

🌬 2. Inhaled Therapies That Reach Biofilms

Doctors are now using or trialling inhaled medications that can:

  • Reach fungal and bacterial biofilms more directly

  • Work even when oral drugs can’t penetrate
    For example, inhaled colistin or tobramycin is used in bronchiectasis; inhaled antifungals (like opelconazole) are in trials for aspergillosis.

💡 3. Chest Physiotherapy and Mucus Clearance

Biofilm research has shown that many infections hide in thick mucus. So, clearing mucus isn't just for comfort — it’s a critical part of treatment.

  • More patients now receive airway clearance devices

  • Some are referred for specialist physiotherapy to support this

🧼 4. Better Infection Control in Hospital

Because we understand that biofilms form on equipment and even in hospital air systems, specialist centres like NAC use:

  • HEPA-filtered rooms

  • Strict protocols to prevent airborne contamination
    This lowers the risk of acquiring new fungal infections during hospital stays.

📊 5. More Personalised Care

Some patients now receive tailored treatment plans based on:

  • Sputum cultures that show which organisms are present

  • Whether biofilm-forming species are involved

  • Coexisting inflammation, allergies, or colonisation patterns

This is a big shift from one-size-fits-all prescriptions.

💬 Final Reassurance

These discoveries don’t mean there’s something worse going on. They mean that:

  • Doctors now understand more

  • Treatments are becoming more precise

  • We can often treat fewer times, more effectively

You're not alone — and you're not expected to keep up with every detail. This information helps your care team make better choices for you, reduce flare-ups, and improve quality of life. And that’s what really matters.

by GAtherton

📝 Article 3: When Microbes Work Together – Aspergillus, Pseudomonas, and Lung Inflammation

🤝 Not all microbes are rivals — some collaborate

Recent research shows that Aspergillus fumigatus and Pseudomonas aeruginosa can cooperate, particularly in people with weakened lungs or structural damage (e.g. from bronchiectasis, CF, or CPA).

Examples of how they interact:

  • Pseudomonas produces toxins (phenazines) that sometimes stimulate Aspergillus growth in low doses

  • Aspergillus produces substances like gliotoxin that weaken immune responses and protect both microbes

  • Both can form mixed biofilms, making them more drug-resistant and more inflammatory

⚠️ Clinical implications:

Coinfection with Aspergillus and Pseudomonas is associated with:

  • Worse lung function in CF, bronchiectasis, CPA

  • More frequent exacerbations and hospital admissions

  • Longer recovery times and lower quality of life

🧠 Why is this important for treatment?

Doctors are now:

  • Testing for multiple microbes during exacerbations

  • Using combination therapy — antifungals and antibiotics together

  • Supporting the immune system with:

    • Airway clearance

    • Nutrition

    • Steroid balancing (not too much, not too little)

🧬 New tools on the horizon:

  • Drugs that block microbial signalling (quorum sensing)

  • Microbiome profiling to predict flare-ups

  • Biofilm-dissolving agents in development

  • Inhaled antifungals under trial (e.g. opelconazole)

🌟 Final Summary: A Shift in Perspective

Old Approach New, Holistic Approach
Target a single infection Understand the whole lung ecosystem
Treat only during active infection Focus on prevention, balance, resilience
One-size-fits-all antibiotic use Tailored therapy, minimise microbiome damage
Ignore biofilms Disrupt biofilms and support mucus clearance
Fungal and bacterial issues separate Recognise synergy and co-infection

by GAtherton

📝 Article 2: The Lung Microbiome – More Than Just Aspergillus

🌱 What is the lung microbiome?

The lung microbiome is the collection of bacteria, fungi, and viruses that naturally live in your respiratory system. For a long time, lungs were thought to be sterile — we now know that they host complex microbial communities, even in healthy people.

In people with chronic lung conditions like CPA, ABPA, asthma, bronchiectasis, and cystic fibrosis, the lung microbiome can become unbalanced. Certain harmful microbes may overgrow, while beneficial ones disappear.

🤝 Why is this important?

The balance of microbes in your lungs affects:

  • How your immune system responds

  • Whether inflammation is triggered or controlled

  • How easily infections take hold

In aspergillosis patients:

  • Disruption of the microbiome may encourage fungal growth

  • Frequent antibiotics (for chest infections) can kill good bacteria, giving fungi and drug-resistant bacteria an advantage

  • Some microbes may protect against Aspergillus or help modulate inflammation

This is particularly important during flare-ups and exacerbations.

🧪 What are researchers doing?

Lung microbiome research is growing rapidly. Scientists are:

  • Identifying "protective" microbes that might reduce disease severity

  • Studying how antibiotics, steroids, and antifungals alter the microbiome

  • Investigating faecal or airway microbiota transplants in severe lung disease

  • Developing tests that detect imbalances in lung flora before symptoms worsen

💡 What can you do as a patient?

  • Avoid unnecessary or repeated broad-spectrum antibiotics unless clearly needed

  • Use airway clearance techniques to keep mucus and debris low

  • Ask your clinician if your sputum cultures test for both bacteria and fungi

  • Consider probiotics cautiously, though evidence for lung benefit is still limited

by GAtherton

📝 Article 1: What Are Biofilms – And Why Do They Matter in Aspergillosis?

🧫 What is a biofilm?

A biofilm is a protective layer that microorganisms (like fungi and bacteria) create when they stick to a surface — such as the inside of airways, lung cavities, or medical devices. They secrete a sticky matrix of sugars, proteins, and DNA that holds them together and shields them from harm.

In aspergillosis, Aspergillus fumigatus forms biofilms on:

  • Mucus in the lungs

  • Cavities or damaged tissue (e.g. in CPA)

  • Surfaces of bronchial airways, especially in people with asthma or bronchiectasis

Pseudomonas aeruginosa, a bacterium often found alongside Aspergillus, also forms biofilms — and they can even form mixed (dual-species) biofilms together.

❗Why does this matter?

Biofilms protect the microbes inside by:

  • Blocking immune cells from reaching them

  • Preventing antibiotics or antifungals from penetrating the biofilm

  • Allowing microbes to go dormant, then reactivate later

This is one reason why infections in aspergillosis patients can become chronic, relapse frequently, or be very hard to fully clear.

People with CPA, ABPA, SAFS, or fungal bronchitis may experience:

  • Repeated flare-ups or infections despite treatment

  • Persistent coughing, breathlessness, or mucus production

  • Ongoing inflammation in the lungs, even when cultures are negative

🛠 How are biofilms treated?

Current options include:

1. Antifungals and antibiotics

  • Standard antifungals (like voriconazole, posaconazole, isavuconazole) can sometimes penetrate biofilms, but often require longer or higher doses.

  • Inhaled antibiotics (e.g. nebulised colistin or tobramycin) are used in bronchiectasis and can help break into bacterial biofilms.

  • Combined therapy (targeting both bacteria and fungi) may be used in patients with co-infection.

2. Disrupting the biofilm

  • DNase (Pulmozyme) in cystic fibrosis breaks up sticky DNA in mucus where biofilms form.

  • Future treatments aim to use enzymes, surfactants, or nanoparticles to dismantle biofilms.

3. Clearing mucus and infected secretions

  • Chest physiotherapy, postural drainage, and devices like the Acapella® or Flutter® help remove secretions where biofilms sit.

  • Bronchoscopy is occasionally used to clear dense mucus plugs.

🔬 Looking ahead:

Researchers are studying:

  • Drugs that target the biofilm matrix directly

  • Ways to prevent biofilms from forming in the first place

  • New diagnostic tools that detect biofilm presence

by GAtherton